OMIM : 152390
GENECARD : ALOX5
CGAP : 89499
SYNONYMS
arachidonate 5-lipoxygenase
Clinical
A phase II study of the 5-lipoxygenase inhibitor, CV6504, in advanced pancreatic cancer: correlation of clinical data with pharmacokinetic and pharmacodynamic endpoints. Ferry DR, Deakin M, Baddeley J, Daryanani S, Bramhall S, Anderson DA, Wakelam MJ, Doran J, Pemberton G, Young AM, Buckels J, Kerr DJ.
Blockade of LOX enzymes may be valuable for the treatment of human pancreatic cancer. Ding XZ, Kuszynski CA, El-Metwally TH, Adrian TE.
Lipoxygenase inhibitors abolish proliferation of human pancreatic cancer cells. Ding XZ, Iversen P, Cluck MW, Knezetic JA, Adrian TE.
The more effective of the two 5-lipoxygenase inhibitors, a synergistic reduction in Panc-1 cell number and viability occurred. Anderson KM, Seed T, Meng J, Ou D, Alrefai WA, Harris JE.
Function
5-Lipoxygenase activity in the human pancreas. Mancini JA, Li C, Vickers PJ.
Oncogenicity
Both 5-LOX and 12-LOX expression is upregulated in human pancreatic cancer cells and LOX plays a critical role in pancreatic cancer cell proliferation. Ding XZ, Iversen P, Cluck MW, Knezetic JA, Adrian TE.
Signaling Pathway
Beta-adrenergic growth regulation of human cancer cell lines derived from pancreatic ductal carcinomas. Weddle DL, Tithoff P, Williams M, Schuller HM.